Skip to main content
SpringerLink
Log in

Epidemiology and Socioeconomic Impact of CNS Metastases

  • Chapter
  • First Online:
Central Nervous System Metastases

Abstract

Brain metastases are the most common tumor of the central nervous system with an overall incidence ranging from 8% to 26%. The most common malignancies to metastasize to the brain are lung, breast, melanoma, renal, and colorectal carcinoma. However, brain metastases are frequently underreported, and recent epidemiologic studies suggest that the true incidence is increasing due to longer patient survival and more sensitive imaging techniques. As advances in life-prolonging treatments with variable blood-brain barrier penetration achieve better control of extracranial disease, the brain has become a common site of late recurrence. Following the diagnosis of brain metastases, patients often experience a significant decline in quality of life and require a substantial increase in health care expenditure. Further epidemiologic studies are needed to better understand the burden of metastatic disease as treatments continue to evolve.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Gavrilovic IT, Posner JB. Brain metastases: epidemiology and pathophysiology. J Neurooncol. 2005;75:5–14.

    Article  PubMed  Google Scholar 

  2. Posner JB, Chernik NL. Intracranial metastases from systemic cancer. Adv Neurol. 1978;19:579–92.

    CAS  PubMed  Google Scholar 

  3. Takakura K, Sano K, Hojo S, Hirano A. Metastatic tumors of the central nervous system. Tokyo/New York: Igaku-Shoin; 1982.

    Google Scholar 

  4. Pickren J, Lopez G, Tsukada Y, Lane W. Brain metastases: an autopsy study. Cancer Treat Symp. 1983;1983(2):295–313.

    Google Scholar 

  5. Guomundsson KR. A survey of tumors of the central nervous system in Iceland during the 10-year period 1954–1963. Acta Neurol Scand. 1970;46:538–52.

    Article  CAS  PubMed  Google Scholar 

  6. Fogelholm R, Uutela T, Murros K. Epidemiology of central nervous system neoplasms: a regional survey in Central Finland. Acta Neurol Scand. 1984;69(3):129–36.

    Article  CAS  PubMed  Google Scholar 

  7. Percy A, Elveback L, Okazaki H, Kurland L. Neoplasms of the central nervous system: epidemiologic considerations. Neurology. 1972;22(1):40–8.

    Article  CAS  PubMed  Google Scholar 

  8. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J Clin Oncol. 2004;22(14):2865–72.

    Article  PubMed  Google Scholar 

  9. Schouten LJ, Rutten J, Huveneers HAM, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer. 2002;94(10):2698–705.

    Article  PubMed  Google Scholar 

  10. Cagney DN, Martin AM, Catalano PJ, Redig AJ, Lin NU, Lee EQ, et al. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017;19(11):1511–21.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Goncalves PH, Peterson S, Vigneau FD, Shore RD, Quarshie WO, Islam K, et al. Risk of brain metastases in patients with non-metastatic lung cancer: analysis of the Metropolitan Detroit Surveillance, Epidemiology, and End Results (SEER) data. Cancer. 2016;122(12):1921–7.

    Article  PubMed  Google Scholar 

  12. Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep. 2012;14:48–54.

    Article  PubMed  Google Scholar 

  13. Duell T, Kappler S, Knoferl B, Schuster T, Hochhaus J, Morresi-Hauf A, et al. Prevalence and risk factors of brain metastases in patients with newly diagnosed advanced non-small-cell lung cancer. Cancer Treat Commun. 2015;4:106–12.

    Article  Google Scholar 

  14. Hubbs JL, Boyd JA, Hollis D, Chino JP, Saynak M, Kelsey CR. Factors associated with the development of brain metastases. Cancer. 2010;116:5038–46.

    Article  PubMed  Google Scholar 

  15. Heon S, Yeap BY, Britt GJ, Costa DB, Rabin MS, Jackman DM, et al. Development of central nervous system metastases in patients with advanced non-small cell lung cancer and somatic EGFR mutations treated with gefitinib or erlotinib. Clin Cancer Res. 2010;16(23):5873–82.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Bajard A, Westeel V, Dubiez A, Jacoulet P, Pernet D, Dalphin JC, et al. Multivariate analysis of factors predictive of brain metastases in localized non-small cell lung carcinoma. Lung Cancer. 2004;45(3):317–23.

    Article  CAS  PubMed  Google Scholar 

  17. Mujoomdar A, Austin JH, Malhotra R, Powell C, Pearson GD, Shiau MC, et al. Clinical predictors of metastatic disease to the brain from non-small cell lung cancer: primary tumor size, cell type, and lymph node metastases. Radiology. 2007;242(3):882–8.

    Article  PubMed  Google Scholar 

  18. Bell DW, Brannigan BW, Matsuo K, Finkelstein DM, Sordella R, Settleman J, et al. Increased prevalence of EGFR-mutant lung cancer in women and in East Asian populations: analysis of estrogen-related polymorphisms. Clin Cancer Res. 2008;14(13):4079–84.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Shi AA, Digumarthy SR, Temel JS, Halpern EF, Kuester LB, Aquino SL. Does initial staging or tumor histology better identify asymptomatic brain metastases with non-small cell lung cancer? J Thorac Oncol. 2006;1(3):205–10.

    Article  PubMed  Google Scholar 

  20. Detterbeck FC, Lewis SZ, Diekemper R, Addrizzo-Harris D, Alberts WM. The stage classification of lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 suppl):7S–37S.

    Article  CAS  PubMed  Google Scholar 

  21. Rangachari D, Yamaguchi N, VanderLaan PA, Folch E, Mahadevan A, Floyd SR, et al. Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. Lung Cancer. 2015;88(1):108–11.

    Article  PubMed  Google Scholar 

  22. Omuro AM, Kris MG, Miller VA, Franceschi E, Shah N, Milton DT, et al. High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib. Cancer. 2005;103(11):2344–8.

    Article  CAS  PubMed  Google Scholar 

  23. Heon S, Yeap BY, Linderman NI, Joshi VA, Butaney M, Britt GJ, et al. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations. Clin Cancer Res. 2012;18(16):4406–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Mamon HJ, Yeap BY, Janne PA, Reblando J, Shrager S, Jaklitsch MT. High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation. J Clin Oncol. 2005;23(7):1530–7.

    Article  PubMed  Google Scholar 

  25. Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med. 2007;356(1):11–20.

    Article  CAS  PubMed  Google Scholar 

  26. Petrelli F, Lazzari C, Ardito R, Borgonovo K, Bulotta A, Conti B, et al. Efficacy of ALK inhibitors on NSCLC brain metastases: a systematic review and pooled analysis of 21 studies. PLoS One. 2018;13(7):e0201425.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  27. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the Surveillance, Epidemiologic, and End Results database. J Clin Oncol. 2016;24(28):4539–44.

    Article  Google Scholar 

  28. Roengvoraphoj O, Eze C, Niyazi M, Li M, Hildebrandt G, Fietkau R, et al. Prognostic role of patient gender in limited-disease small-cell lung cancer treated with chemoradiotherapy. Strahlenther Onkol. 2017;193:150–5.

    Article  PubMed  Google Scholar 

  29. Gong L, Wang QI, Zhao L, Yuan Z, Li R, Wang P. Factors affecting the risk of brain metastasis in small cell lung cancer with surgery: is prophylactic cranial irradiation necessary for stage I-III disease? Int J Radiat Oncol Biol Phys. 2012;85(1):196–200.

    Article  PubMed  Google Scholar 

  30. Schild SE, Foster NR, Meyers JP, Ross HJ, Stella PJ, Garces YI, et al. Prophylactic cranial irradiation in small-cell lung cancer: findings from a North Central Cancer Treatment Group Pooled Analysis. Ann Oncol. 2012;23(11):2919–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Rudin CM, Ismaila N, Hann CL, Malhotra N, Movsas B, Norris K. Treatment of small-cell lung cancer: American Society of Clinical Oncology endorsement of the American College of Chest Physicians guideline. J Clin Oncol. 2015;33(34):4106–11.

    Article  CAS  PubMed  Google Scholar 

  32. Auperin A, Arriagada R, Pignon J-P, Le Pechoux C, Gregor A, Stephens RJ, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999;341:476–84.

    Article  CAS  PubMed  Google Scholar 

  33. Ge W, Xu H, Yan Y, Cao D. The effects of prophylactic cranial irradiation versus control on survival of patients with extensive-stage small-cell lung cancer: a meta-analysis of 14 trials. Radiat Oncol. 2018;13:155.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  34. Wolfson AH, Bae K, Komaki R, Meyers C, Movsas B, Le Pechoux C, et al. Primary analysis of a phase II randomized trial Radiation Therapy Oncology Group (RTOG) 0212: impact of different total doses and schedules of prophylactic cranial irradiation on chronic neurotoxicity and quality of life for patients with limited-disease small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011;81(1):77–84.

    Article  PubMed  Google Scholar 

  35. Lok BH, Ma J, Foster A, Perez CA, Shi W, Zhang Z, et al. Factors influencing the utilization of prophylactic cranial irradiation in patients with limited-stage small cell lung cancer. Adv Radiat Oncol. 2017;2(4):548–54.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Lattuca-Truc M, Levra MG, Ruckly S, Villa J, Dumas I, Julian P. Trends in response rate and survival in small cell lung cancer patients between 1997 and 2017. J Clin Oncol. 2018;36:e20572.

    Article  Google Scholar 

  37. Stemmler H-J, Heinemann V. Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challenge. Oncologist. 2008;13:739–50.

    Article  PubMed  Google Scholar 

  38. Miller KD, Weathers T, Haney LG, Timmerman R, Dickler M, Shen J, et al. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann Oncol. 2003;14:1072–7.

    Article  CAS  PubMed  Google Scholar 

  39. Bachmann C, Schmidt S, Staebler A, Fehm T, Fend F, Schittenhelm J, et al. CNS metastases in breast cancer patients: prognostic implications of tumor subtype. Med Oncol. 2015;32:400.

    Article  CAS  PubMed  Google Scholar 

  40. Frisk G, Svensson T, Backlund LM, Lidbrink E, Blomqvist P, Smedby KE. Incidence and time trends of brain metastases admissions among breast cancer patients in Sweden. Br J Cancer. 2012;106:1850–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Martin AM, Cagney DN, Catalano PJ, Warren LE, Bellon JR, Punglia RS, et al. Brain metastases in newly diagnosed breast cancer: a population-based study. JAMA Oncol. 2017;3(8):1069–77.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Musolino A, Ciccolallo L, Panebianco M, Fontana E, Zanoni D, Bozzetti C, et al. Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study. Cancer. 2011;117(9):1837–46.

    Article  PubMed  Google Scholar 

  43. Albiges L, Andre F, Balleyguier C, Gomez-Abuin G, Chompret A, Delaloge S. Spectrum of breast cancer metastasis in BRCA1 mutation carriers: highly increased incidence of brain metastases. Ann Oncol. 2005;16(11):1846–7.

    Article  CAS  PubMed  Google Scholar 

  44. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244(4905):707–12.

    Article  CAS  PubMed  Google Scholar 

  45. Slimane K, Andre F, Delaloge S, Dunant A, Perez A, Grenier J, et al. Risk factors for brain relapse in patients with metastatic breast cancer. Ann Oncol. 2004;15:1640–4.

    Article  CAS  PubMed  Google Scholar 

  46. Bria E, Cuppone F, Fornier M, Nistico C, Carlini P, Milella M, et al. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials. Breast Cancer Res Treat. 2008;109:231–9.

    Article  CAS  PubMed  Google Scholar 

  47. Duchnowska R, Szczylik C. Central nervous system metastases in breast cancer patients administered trastuzumab. Cancer Treat Rev. 2005;31:312–8.

    Article  CAS  PubMed  Google Scholar 

  48. Romond EH, Perez EA, Bryant J, Suman V, Geyer CE, Davidson NE, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353:1673–84.

    Article  CAS  PubMed  Google Scholar 

  49. Olson EM, Abdel-Rasoul M, Maly J, Wu CS, Lin NU, Shapiro CL. Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab. Ann Oncol. 2013;24:1526–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Petrelli F, Ghidini M, Lonati V, Tomasello G, Borgonovo K, Ghilardi M, et al. The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: a systemic review and pooled analysis. Eur J Cancer. 2017;84:141–8.

    Article  CAS  PubMed  Google Scholar 

  51. Patel JK, Didolkar MS, Pickren JW, Moore RH. Metastatic pattern of malignant melanoma: a study of 216 autopsy cases. Am J Surg. 1978;135(6):807–10.

    Article  CAS  PubMed  Google Scholar 

  52. Davies MA, Liu P, McIntyre S, Kim KB, Papadopoulos N, Hwu W-J, et al. Prognostic factors for survival in melanoma patients with brain metastases. Cancer. 2011;117(8):1687–96.

    Article  PubMed  Google Scholar 

  53. Acharya S, Mahmood M, Mullen D, Yang D, Tsien CI, Huang J, et al. Distant intracranial failure in melanoma brain metastases treated with stereotactic radiosurgery in the era of immunotherapy and targeted agents. Adv Radiat Oncol. 2017;2:572–80.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Sloan AE, Nock CJ, Einstein DB. Diagnosis and treatment of melanoma brain metastasis: a literature review. Cancer Control. 2009;16(3):248–55.

    Article  PubMed  Google Scholar 

  55. Zhang D, Wang Z, Shang D, Yu J, Yuan S. Incidence and prognosis of brain metastases in cutaneous melanoma patients: a population-based study. Melanoma Res. 2019;29(1):77–84.

    Article  PubMed  Google Scholar 

  56. Sloot S, Chen YA, Zhao X, Weber JL, Benedict JJ, Mule JJ, et al. Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies. Cancer. 2017;124(2):297–305.

    Article  PubMed  CAS  Google Scholar 

  57. Coit DG, Thompson JA, Algazi A, Andtbacka R, Bichakjian CK, Carson WE, et al. Melanoma, version 2.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2016;14(4):450–73.

    Article  PubMed  Google Scholar 

  58. Zakrzewski J, Geraghty LN, Rose AE, Christos PJ, Mazumdar M, Polsky D, et al. Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post-brain metastases survival. Cancer. 2011;117(8):1711–20.

    Article  PubMed  Google Scholar 

  59. Ramakrishna N, Margolin KA. Multidisciplinary approach to brain metastasis from melanoma; local therapies for central nervous system metastases. Am Soc Clin Oncol Educ Book. 2013;33:399–403.

    Article  Google Scholar 

  60. Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379:722–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Iorgulescu JB, Harary M, Zogg CK, Ligon KL, Reardon DA, Hodi FS, et al. Improved risk-adjusted survival for melanoma brain metastases in the era of checkpoint blockade immunotherapies: results from a national cohort. Cancer Immunol Res. 2018;6(9):1039–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  62. Gaudy-Marqueste C, Dussouil AS, Carron R, Troin L, Malissen N, Loundou A, et al. Survival of melanoma patients treated with targeted therapy and immunotherapy after systematic upfront control of brain metastases by radiosurgery. Eur J Cancer. 2017;84:44–54.

    Article  CAS  PubMed  Google Scholar 

  63. Gabani P, Fischer-Valuck BW, Johanns TM, Hernandez-Aya LF, Keller JW, Rich KM, et al. Stereotactic radiosurgery and immunotherapy in melanoma brain metastases: patterns of care and treatment outcomes. Radiother Oncol. 2018;128:266–73.

    Article  PubMed  Google Scholar 

  64. Qian JM, Yu JB, Kluger HM, Chiang VLS. Timing and type of immune checkpoint therapy affect the early radiographic response of melanoma brain metastases to stereotactic radiosurgery. Cancer. 2016;122:3051–8.

    Article  CAS  PubMed  Google Scholar 

  65. Patel KR, Shoukat S, Oliver DE, Chowdhary M, Rizzo M, Lawson DH, et al. Ipilimumab and stereotactic radiosurgery versus stereotactic radiosurgery alone for newly diagnosed melanoma brain metastases. Am J Clin Oncol. 2017;40(5):444–50.

    Article  CAS  PubMed  Google Scholar 

  66. Davies MA, Saiad P, Robert C, Grob J-J, Flaherty KT, Arance A, et al. Dabrafenib plus trametinib in patients with BRAF V600–mutant melanoma brain metastases (COMBI-MB): a multi-cohort, open-label, phase 2 trial. Lancet Oncol. 2017;18(7):863–73.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Schuch B, La Rochelle JC, Klatte T, Riggs SB, Liu W, Kabbinavar FF, et al. Brain metastasis from renal cell carcinoma. Cancer. 2008;113(7):1641–8.

    Article  Google Scholar 

  68. Sun M, De Velasco G, Brastianos PK, Aizer AA, Martin AM, Moreira R, et al. The development of brain metastases in patients with renal cell carcinoma: epidemiologic trends, survival, and clinical risk factors using a population-based cohort. Eur Urol Focus. 2018;S2405–4569(17):30294–8.

    Google Scholar 

  69. Massard C, Zonierek J, Gross-Goupil M, Fizazi K, Szczylik C, Escudier B. Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Ann Oncol. 2010;21:1027–31.

    Article  CAS  PubMed  Google Scholar 

  70. Ranze O, Hofmann E, Distelrath A, Hoeffkes HG. Renal cell cancer presented with leptomeningeal carcinomatosis effectively treated with sorafenib. Onkologie. 2007;30(8–9):450–1.

    PubMed  Google Scholar 

  71. Thibault F, Billemont B, Rixe O. Regression of brain metastases of renal cell carcinoma with antiangiogenic therapy. J Neurooncol. 2008;86(2):243–4.

    Article  PubMed  Google Scholar 

  72. Medioni J, Cojocarasu O, Belcaceres JL, Halimi P, Oudard S. Complete cerebral response with sunitinib for metastatic renal cell carcinoma. Ann Oncol. 2007;18(7):1282–3.

    Article  CAS  PubMed  Google Scholar 

  73. Lauko A, Thapa B, Jia X, Ahluwalia MS. Efficacy of immune checkpoint inhibitors in patients with brain metastasis from NSCLC, RCC, and melanoma. J Clin Oncol. 2018;36(5_suppl):214.

    Article  Google Scholar 

  74. Christensen TD, Spindler K-LG, Palshof JA, Nielsen DL. Systemic review: brain metastases from colorectal cancer — incidence and patient characteristics. BMC Cancer. 2016;16:260.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  75. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol. 2004;22(7):1209–14.

    Article  CAS  PubMed  Google Scholar 

  76. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–42.

    Article  CAS  PubMed  Google Scholar 

  77. Sundermeyer ML, Meropol NJ, Rogatko A, Wang H, Cohen SJ. Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer. 2005;5(2):108–13.

    Article  PubMed  Google Scholar 

  78. Yaeger R, Cowell E, Chou JF, Gewirtz AN, Borsu L, Vakiani E, et al. RAS mutations affect pattern of metastatic spread and increase propensity for brain metastasis in colorectal cancer. Cancer. 2014;121(8):1195–203.

    Article  PubMed  CAS  Google Scholar 

  79. Wong MCS, Goggins WB, Wang HHX, Fung FDH, Leung C, Wong SYS, et al. Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries. Eur Urol. 2016;70(5):862–74.

    Article  PubMed  Google Scholar 

  80. SEER cancer statistics review, 1975–2015, National Cancer Institute. Bethesda, MD [Internet]. 2018 [cited December 15, 2018]. Available from: https://seer.cancer.gov/csr/1975_2015/.

  81. Tremont-Lukats IW, Bobustuc G, Lagos GK, Lolas K, Kyritsis AP, Puduvalli VK. Brain metastasis from prostate carcinoma: the M. D. Anderson Cancer Center experience. Cancer. 2003;98(2):363–8.

    Article  PubMed  Google Scholar 

  82. Caffo O, Gernone A, Ortega C, Sava T, Carteni G, Facchini G, et al. Central nervous system metastases from castration-resistant prostate cancer in the docetaxel era. J Neurooncol. 2012;107:191–6.

    Article  PubMed  Google Scholar 

  83. Mahmoud-Ahmed AS, Suh JH, Kupelian PA, Klein EA, Peereboom DM, Dreicer R, et al. Brain metastases from bladder carcinoma: presentation, treatment and survival. J Urol. 2002;167:2419–22.

    Article  PubMed  Google Scholar 

  84. Pietzner K, Oskay-Oezcelik G, Khalfaoui K, Boehmer D, Lightenegger W, Sehouli J. Brain metastases from epithelial ovarian cancer: overview and optimal management. Anticancer Res. 2009;29(7):2793–8.

    PubMed  Google Scholar 

  85. Pakneshan S, Safarpour D, Tavassoli F, Jabbari B. Brain metastasis from ovarian cancer: a systematic review. J Neurooncol. 2014;119:1–6.

    Article  PubMed  Google Scholar 

  86. Fetcko K, Gondim DD, Bonnin JM, Dey M. Cervical cancer metastasis to the brain: a case report and review of literature. Surg Neurol Int. 2017;8:181.

    Article  PubMed  PubMed Central  Google Scholar 

  87. Piura E, Piura B. Brain metastases from endometrial carcinoma. ISRN Oncol. 2012;2012:581749.

    PubMed  PubMed Central  Google Scholar 

  88. Vrachimis A, Schmid KW, Jurgens H, Schober O, Wekesser M, Riemann B. Cerebral metastases from thyroid carcinoma: complete remission following radioiodine treatment. Dtsch Arztebl Int. 2013;110(50):861–6.

    PubMed  PubMed Central  Google Scholar 

  89. Chiu AC, Delpassand ES, Sherman SI. Prognosis and treatment of brain metastases in thyroid carcinoma. J Clin Endocrinol Metab. 1997;82(11):3637–42.

    Article  CAS  PubMed  Google Scholar 

  90. Pelletier EM, Shim B, Goodman S, Amonkar MM. Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis. Breast Cancer Res Treat. 2008;108:297–305.

    Article  PubMed  Google Scholar 

  91. Guerin A, Sasane M, Dea K, Zhang J, Culver K, Nitulescu R, et al. The economic burden of brain metastasis among lung cancer patients in the United States. J Med Econ. 2016;19(5):526–36.

    Article  CAS  PubMed  Google Scholar 

  92. Guerin A, Sasane M, Zhang J, Culver KW, Dea K, Nitulescu R. Brain metastases in patients with ALK+ non-small cell lung cancer: clinical symptoms, treatment patterns and economic burden. J Med Econ. 2015;18(4):312–22.

    Article  PubMed  Google Scholar 

  93. Vekeman F, Cloutier M, Yermakov S, Amonkar MM, Arondekar B, Duh MS. Economic burden of brain metastases among patients with metastatic melanoma in a USA managed care population. Melanoma Res. 2014;24:602–10.

    Article  CAS  PubMed  Google Scholar 

  94. Peters S, Bexelius C, Munk V, Leighl N. The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer. Cancer Treat Rev. 2016;45:139–62.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Jessica A. Wilcox & Lisa M. DeAngelis

Authors
  1. Jessica A. Wilcox
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lisa M. DeAngelis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lisa M. DeAngelis .

Editor information

Editors and Affiliations

  1. Department of Neurological Surgery, NewYork-Presbyterian Hospital/Weill Cornell Medicine, Director - Brain Metastases Program, New York, NY, USA

    Rohan Ramakrishna

  2. Department of Neurology, NewYork-Presbyterian Hospital/Weill Cornell Medicine, New York, NY, USA

    Rajiv S. Magge

  3. Department of Neurological Surgery, NewYork-Presbyterian Hospital/Weill Cornell Medicine, New York, NY, USA

    Ali A. Baaj

  4. Department of Radiation Oncology, NewYork-Presbyterian Hospital/Weill Cornell Medicine, New York, NY, USA

    Jonathan P.S. Knisely

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Wilcox, J.A., DeAngelis, L.M. (2020). Epidemiology and Socioeconomic Impact of CNS Metastases. In: Ramakrishna, R., Magge, R., Baaj, A., Knisely, J. (eds) Central Nervous System Metastases. Springer, Cham. https://doi.org/10.1007/978-3-030-42958-4_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-42958-4_1

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-42957-7

  • Online ISBN: 978-3-030-42958-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation